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Background: In a recent study one third of Lao patients presenting with uncomplicated Plasmodium falciparum
malaria had biochemical evidence of thiamin deficiency, which was associated with a higher incidence of adverse
events. Thiamin supplementation might, therefore, reduce adverse events in this population.
Methods: An exploratory, double-blind, parallel group, placebo-controlled, superiority trial of thiamin supplementation
in patients of all ages with uncomplicated and severe falciparum malaria was conducted in Xepon District, Savannakhet
Province, southern Laos. Patients were randomly assigned to either oral thiamin 10 mg/day for 7 days immediately after
standard anti-malarial treatment then 5 mg daily until day 42, or identical oral placebo.
Results: After interim analyses when 630 patients (314 in thiamin and 316 in placebo groups) had been recruited, the
trial was discontinued on the grounds of futility. On admission biochemical thiamin deficiency (alpha≥ 25%) was
present in 27% of patients and 9% had severe deficiency (alpha > 31%). After 42 days of treatment, the frequency of
thiamin deficiency was lower in the thiamin (2%, 1% severe) compared to the placebo (11%, 3% severe) groups (p < 0.001
and p = 0.05), respectively. Except for diarrhoea, 7% in the placebo compared to 3% in the thiamin group (p = 0.04), and
dizziness on day 1 (33% vs 25%, p = 0.045), all adverse events were not significantly different between the groups (p > 0.05).
Clinical, haematological, and parasitological responses to treatment did not differ significantly between the two groups.
Conclusion: Thiamin supplementation reduced biochemical thiamin deficiency among Lao malaria patients
following anti-malarial drug treatment, but it did not reduce the frequency of adverse events after anti-malarial
therapy or have any detected clinical or parasitological impact.
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Malaria remains an important cause of morbidity and
mortality in rural Lao PDR (Laos) particularly in the
southern provinces [1-3]. In 2005, the Lao government
changed the nationally recommended treatments for
uncomplicated Plasmodium falciparum malaria from
chloroquine (CQ) and sulphadoxine-pyrimethamine
(SP) to artemisinin-based combination therapy (ACT)
(artemether-lumefantrine), which has been highly effi-
cacious [2,3].
Malaria morbidity and mortality burden is increased
by micronutrient deficiencies and malnutrition [4]. In
western Thailand, adults with malaria, especially those
with severe malaria, had biochemical evidence for thia-
min deficiency [5]. One third of Lao patients presenting
with uncomplicated falciparum malaria in southern Laos
had evidence for biochemical thiamin deficiency and
12% had unequivocal evidence for severe deficiency [6].
Infantile beriberi is common in some communities in
Laos [7,8] but there are no data on biochemical thiamin
deficiency in older Lao children or adults without mal-
aria. In the malaria studies the proportion of patients
with biochemical thiamin deficiency was significantly
lower at 42 day follow up, but patients received thiamin
supplementation during recovery so it was uncertain
whether this reduction was a consequence of recovery
from malaria or thiamin supplementation or both. In a
post-hoc analysis (unpublished), the estimated median
(range) admission basal erythroycte transketolase activity
(ETK) but not the activation coefficient (alpha), was sig-
nificantly lower in those who developed one or more ad-
verse effects during or after treatment than those who
did not (p = 0.003). This measure was significantly lower
in those with dizziness, headache, and nightmares than
in those without (p < 0.001). Shortness of breath before
treatment was associated with lower median (range)
admission extrapolated basal ETK (p = 0.002), whilst
shortness of breath after treatment was not. In the
Wenicke-Korsakoff syndrome, ataxia is a cardinal fea-
ture and dizziness has been reported [9]. Thiamin, es-
pecially as thiamin triphosphate, is important in brain
function [10]. Nightmares have not been described
previously in beriberi or subclinical thiamin deficiency.
Whether the associations of adverse events with sub-
clinical thiamin deficiency are related to the drug or to
malaria or interaction between the two factors is un-
clear. That dizziness was associated with low extrapo-
lated basal ETK both before and after anti-malarial
treatment suggests that the association may be a con-
sequence of malaria and not the anti-malarial treat-
ment. In the earlier studies in Laos Mayxay et al. [6]
did not include patients with severe malaria, young
children or pregnant women, who would be expected
to have a higher incidence of thiamin deficiency.Neurological adverse events, whether attributable to
malaria and anti-malarial drugs, are important aspects
of morbidity during malaria and recovery [11] and any
measure to reduce their frequency would be of public
health importance.
An exploratory, double-blind, parallel group, placebo-
controlled, superiority trial of thiamin supplementation
was conducted in patients of all ages with uncomplicated
and severe falciparum malaria to assess the frequency
and severity of biochemical thiamin deficiency and its
relationship to malaria severity and whether thiamin
supplementation reduces the frequency of adverse events
after anti-malarial therapy.
Methods
Trial design, patients, clinical and laboratory procedures
This was an exploratory, double-blind, parallel group,
placebo-controlled, randomized (variable blocks), super-
iority trial conducted between June and November from
2008–2010 at Xepon (30 beds) Inter-District Hospital
(16.69° N, 106.20° E, 208 metres above mean sea level),
Savannakhet Province, ~665 km south-east of Vientiane,
the capital of Laos. Xepon (88 villages, population 48,000)
is inhabited predominantly by rice farmers of the Lao
Theung ethnic groups. Malaria transmission is sea-
sonal with a peak during the rainy months of July and
August [2,3].
In previous prospective trials at Phalanxay Clinic in
the same Province (~60 Km west of Xepon), 247/550
(49%) patients had at least one potential adverse event
noted [12,13]. A sample size calculation assuming that
50% of patients would have a potential adverse event,
aiming for a power of 80% and level of significance of
5% and a clinically significant difference of 20% in ad-
verse effect frequency, with a ~5% drop out rate, sug-
gested that 814 patients should be recruited (407 to each
arm). A follow up of 42 days was planned.
Patients of any age were included in the trial provided
that they or their guardians (in the case of children) gave
informed written consent, had microscopically-confirmed
P. falciparum infection or mixed Plasmodium species in-
fections, with a history of fever, were willing and expected
to be able to comply with the study protocol for the dur-
ation of the 42 days follow up, and had not taken a full
course of any anti-malarial drugs in the previous three
days. Patients were excluded if they had a history of
hypersensitivity to thiamin or artemether-lumefantrine,
presented with intercurrent non-malarial illness, had clin-
ically apparent suspected thiamin deficiency (beriberi)
[14] or any condition, which in the judgment of the inves-
tigator would place the subject at undue risk or interfere
with the results of the study.
Patients’ admission clinical details including current
and past medical history, pre-treatment, and findings
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record form. Venous blood samples were taken for the
base line assay of washed red cell ETK (see below), para-
site counts, haematocrit, blood glucose, and lactate,
and three blood spots were collected on 3MM filter
paper (Whatman, Maidstone, UK) and stored in a plas-
tic bag with silica gel for later malaria genotype ana-
lysis [2,15]. For women of child-bearing age a urinary
pregnancy test (Orchid+, True Line Med Co., Ltd,
Bangkok, Thailand) was performed before anti-malarial
treatment was prescribed. Children were defined as
those aged <15 years.
Randomization was 1:1 to either thiamin or identical
placebo. The random numbers, generated by a study
doctor who did not enrol patients, corresponded to an
opaque sealed envelope and plastic tablet container con-
taining either thiamin tablets or visually identical place-
bos, prepared by a pharmacist not involved in patient
recruitment. Only the study doctor who performed the
randomization held the master randomization list and
knew the contents of each container. If the study criteria
were met, patients were admitted to the hospital and
randomized (in variable blocks – the assigned treatment
number in a sealed opaque envelope was opened only
after the decision to recruit had been made and consent
form signed) to receive study drugs: either oral thiamin
(5 mg capsule) (Olan-Kemed Co.Ltd, Bangkok, Thailand)
two capsules immediately after anti-malarial drugs, followed
by two capsules daily for seven days followed by one capsule
daily until day 42 or identical placebo, which had the same
appearance as the thiamin capsule and was manufactured
by the same company (Olan-Kemed Co. Ltd, Bangkok,
Thailand).
Ingestion of both anti-malarials and study drugs was
taken within < 20 minutes after enrolment and was dir-
ectly observed for patients in hospital and capsule con-
tainers checked for the number of capsules left at each
subsequent visit. Patients with severe malaria who were
unable to take oral medication started oral thiamin or
placebo (according to the randomization above) as soon
as they were able to. Severe malaria was defined accord-
ing to the World Health Organization [16].
Malaria was treated with the nationally recommended
anti-malarials [17]. Patients with uncomplicated disease
and pregnant patients in the 2nd or 3rd trimesters who
were able to swallow tablets, were treated with artemether
(20 mg)-lumefantrine (120 mg) (AL, Co-artem®, Novartis):
one dose twice daily for three days. Dosing by body weight
were one tablet if <15 kg, two tablets if 15–24 kg, three
tablets if 25–34 kg, and four tablets if ≥35 kg. All patients
were asked to take fatty food with the anti-malarial drugs
and drug administration was directly observed by a study
nurse. For children who could not swallow tablets, the ap-
propriate drug dose was crushed and mixed with waterand given in a syringe. Severe malaria patients were
treated with artesunate (Guilin Pharmaceutical Co.
Ltd.) 2.4 mg/kg IV stat, followed by 2.4 mg/kg IV at
12 hours and 24 hours and then daily until able to take
oral medication when they were given artemether-
lumefantrine for 3 days as above. Pregnant patients in
the first trimester were given quinine (Thai Govern-
ment Pharmaceutical Organization [GPO]) plus clinda-
mycin (Thai GPO) (WHO 2006). Patients who had
recurrent P. falciparum parasitaemia and did not have con-
traindications to mefloquine were treated with artesunate
4 mg/kg/day in single daily dose for 3 days (D0-D2) (Guilin
Pharmaceutical Co. Ltd.) +mefloquine 15 mg/kg on D1
and 10 mg/kg on D2 in single daily doses (Lariam™, Roche
Co.). Patients with contraindications to mefloquine and
were aged >8 years, were treated with artesunate (as above)
and doxycycline (Bangkok Lab & Cosmetic Co., Ltd,
Bangkok, Thailand) 4 mg/kg/day for 7 days. Those who
had P. vivax appearance during follow up were treated
with chloroquine (Thai GPO) (25 mg base/kg) over three
days and further followed up.
Patients were observed for at least one hour after drug
administration and all episodes of vomiting recorded. If
vomiting occurred within 30 minutes of anti-malarial
and/or thiamin/placebo administration, the full dose was
repeated. Patient who vomited within 30 minutes to one
hour, a half dose was re-administered. If the patient
vomited >2 times within one hour, he/she was treated as
for severe malaria (see above).
Vital signs (axillary temperature, pulse, respiratory
rate, and blood pressure) were measured every six hours.
Patients and parasite counts were reviewed daily until
two consecutive negative blood smears, then weekly for
42 days from the start of treatment or at other times if
patients felt unwell. Patients were discharged only when
their fever and parasitaemia had cleared (defined as axil-
lary temperature <37.5°C and 0 parasite per 500 white
cells on thick film after two consecutive negative slides,
respectively) and were asked to return to the hospital at
days 7, 14, 21, 28, 35 and 42 (or at any time the patients
feel unwell) or were visited at home in case the patients
did not return as planned.
At each weekly visit, the symptoms of the patients during
the previous week were recorded. Details of any new medi-
cations taken were recorded and medicines examined to
check whether they contained thiamin. Finger-prick blood
samples were taken for malaria blood smears and haemato-
crit and blood spots were collected onto filter paper strips
from all patients with recurrent fever or malaria symptoms.
One ml of heparinized venous blood samples was taken
from all patients at day 42 for convalescent ETK. PCR
amplification was performed on paired samples for parasite
genotyping to distinguish between reinfection and recru-
descence using three parasite loci (MSP-1, MSP-2, and
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Mahidol-Oxford Tropical Medicine Research Unit (MORU)
malaria molecular laboratory, Bangkok, Thailand. Finger-
prick blood glucose and lactate were determined using
Accu-Chek Advantage II (Roche Diagnostics Manufactures)
and Accutrend® (Roche Diagnostics Manufactures) devices,
respectively.
The occurrence of adverse events was determined pro-
spectively. Anorexia, nausea, headache, vomiting, dreams,
nightmares, abdominal pain, paraesthesia, ability to rise
from squatting position, diarrhoea, vertigo, rash and itch
were asked about at each visit. A visual analogue scale
(VAS; 0–10) was used to measure the severity of headache
and vertigo. Particular attention was given to record and
distinguish dreams and nightmares (unpleasant dreams as
defined by the patient) and these were only asked from
those aged >4 years. A cardiovascular examination,
looking for signs of heart failure, was performed on ad-
mission and days 2, 7 and 42. A brief neurological
examination was performed on admission, on day 2
and then on days 7 and 42. This included tests for co-
ordination (heel-toe ataxia), fine finger dexterity (abil-
ity to pick up a 500 mg paracetamol tablet that is
10 mm diameter and 0.5 mm thick), nystagmus and
balance (assessment of sway when standing with feet
together and eyes shut) [18] and ability of those >5 years
old to rise from a squatting position.
Red cell transketolase activity assays
Immediately after collection, the lithium heparin anticoa-
gulated blood was centrifuged and washed in phosphate
buffered saline three times, with removal of the buffy coat
initially and after each wash. Washed red cell samples
were stored at −30°C for maximum of 3 months and then
at −70°C until shipment to the UK on dry ice. Red cell
transketolase activity assays were performed in Cambridge
using an adaptation of the method of Vuilleumier et al.
[19] as described in Khounnorath et al. [7] and Soukaloun
et al. [8]. These are the functional assays for the thiamin-
dependent erythrocyte transketolase enzyme in washed
red cells. The activation coefficient (alpha) is the ratio of
in vitro erythrocyte transketolase activity (ETK) after thia-
min pyrophosphate has been added minus the basal ETK
before thiamin pyrophosphate has been added, to the
basal ETK, expressed as a percentage. Higher alpha coeffi-
cients represent greater degrees of thiamin deficiency. In
contrast to an earlier study Mayxay et al. [6] haemoglobin
was measured to calculate ETK [19]. Categories of α
of <15, 15–24, 25–31 and >31% were used with α >31%
[5,6] defining severe biochemical deficiency. Although
previous studies in Laos [7,8] demonstrated that basal
ETK and to a lesser extent activated ETK, and not the
alpha coefficient, is the best biochemical marker of thia-
min deficiency in infants, the alpha value was used todetermine whether patients were thiamin deficient be-
cause the majority (97%) of recruited patients were not
infants.
Written informed consent was obtained from all par-
ticipants. Ethical clearance for the study was granted by
the Lao National Ethics Committee for Health Research
and the Oxford University Tropical Medicine Research
Ethics Committee (OXTREC). The trial is registered as
ISRCTN: 85411059. A Data and Safety Monitoring
committee (DMC), including a statistician familiar with
clinical trials and three doctors familiar with thiamin defi-
ciency, malaria and clinical trials, was set up to perform
interim analyses at the end of each trial season (the rainy
season). The trial was monitored by the Clinical Trials
Support Group of MORU, Bangkok, Thailand.
Outcome measures
The primary objective of the trial was to determine
whether the frequency of adverse events, after initiation
of anti-malarial treatment, was significantly lower in
those who received thiamin supplementation in com-
parison to those who did not. The secondary objective
was to determine the frequency of biochemical thiamin
deficiency and whether this was related to the clinical
severity of disease and to compare resolution of defi-
ciency between those who did and did not receive thia-
min supplementation. The following outcomes were also
reported: PCR-corrected adequate clinical and parasito-
logical responses at day 42 [20], the PCT (the time in
hours from the first treatment dose to the first of two
consecutive thick films that were negative for asexual
falciparum parasites after checking ≥500 oil fields) and
fever clearance times (FCT, time in hours from the start
of treatment at which the tympanic temperature first
dropped below 37.5°C and remained below 37.5°C for
48 hours) following anti-malarial treatment. These have
been reported, in part, in Mayxay et al. [3].
Statistical analysis
Data were analysed using Stata v9 (StataCorp, College
Station, TX, USA). Comparisons between two groups
were made by the Mann–Whitney U, Student’s t, chi-
square, and Fisher’s exact tests, as appropriate. Cure
rates were calculated as the proportion of patients with
PCR-confirmed recrudescence using intention-to-treat
(ITT) and per-protocol (PP) populations and by Kaplan-
Meier survival analysis. In the ITT population all losses
to follow-up were treated as failures and in the PP popu-
lation losses to follow-up were excluded from the ana-
lysis. Patients with new infections were regarded as
cures in both analyses. Gametocyte carriage was summa-
rized as person-gametocytes-week rates calculated as the
total number of weeks with gametocytes divided by the
total number of weeks of follow-up.
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At the end of the third trial season when 630 patients
had been recruited, following an interim analysis, the
DMC advised that the study should be discontinued on
the grounds of futility, with evidence that the study could
not meet its primary endpoint. Of 630 patients enrolled in
the trial [619 (98%) with P. falciparum mono-infection and
11 (2%) with mixed infections (10 P. falciparum + Plasmo-
dium vivax and one P. falciparum + Plasmodium malar-
iae)], 314 and 316 received thiamin and identical
placebo, respectively (Figure 1). Forty-two day follow
up was completed for 309 (98%) in the thiamin and
308 (97%) in the placebo groups (Figure 1). Two pa-
tients (one in each arm) had persistent vomiting after
taking AL, 7 (4 in thiamin and 3 in placebo groups)Thiamin 
314 
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Analysis of thiamin intervention medicine and patient
adherence
High-performance liquid chromatography (HPLC), using
the method of the United States Pharmacopeia [21], of
three randomly selected thiamin tablets gave %API of
91, 93, and 92%. Capsule counts at visits following dis-
charge from hospital suggested that 6% of all patients
(5% in thiamin and 6% in placebo groups, p = 0.62) did
not finish their thiamin/placebo capsules. The patients
stated that the reason for not finishing them was that
they forgot. The overall median (range) days that the pa-
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placebo [3.5 (1–8) days] groups (p = 0.94).
Demographic, clinical and laboratory details on admission
Patient admission demographic, clinical and laboratory
details differed little between the thiamin and placebo
groups (Table 1). All patients in both groups had a his-
tory of fever before admission and 471 (75%) were fe-
brile at the time of enrollment. Twenty-nine (5%) patients
were pregnant, 414 (66%) were children, 21 (3%) were in-
fants, and 34 (5%) had severe malaria [16]. The admission
symptoms and signs, and median (range) headache and
dizziness visual analogue scores were not different be-
tween two groups (Table 2).Table 1 Admission demographic, clinical and laboratory deta
treatment and Plasmodium falciparum malaria in Laos
Variables Treatment gr
All (N = 630)
Sex, M, no (%) 317 (50)
Age, years, median (range) 8 (0.5 – 73)
No. (%) patients aged <15 years 414 (66)
Body weight, kg 28.1 (26.8 – 29
Height, cm 122.1 (119.9 –
Previous malaria attack, no. (%) of patientsa 166 (26)
Axillary temperature, °C 38.4 (38.3 – 38
Patients without fever on admission, no. (%) 159 (25)
Systolic blood pressure, mm Hg 100.8 (99.8 – 1
Diastolic blood pressure, mm Hg 68.8 (68.0 – 69
Pulse, beats/min 96.4 (95.2 – 97
Respiratory rate/min 28.1 (27.6 – 28
Glasgow coma score, median (range) 15 (4 – 15)
Severe malaria, no. (%) [WHO, 2000] 34 (5)
Pregnancy, no. (%) 29 (5)
Headache visual analogue score* 5.2 (5.0 – 5.5)
Dizziness visual analogue score, median (range)* 4 (0 – 10)
Splenomegaly, no. (%) of patients 163/628 (26)
Hepatomegaly, no (%) of patients 143/627 (23)
Lymphadenopathy, no (%) of patients 2/629 (0.3%)
Parasitaemia, geometric mean parasites/μL (95%CI) 25,677 (22,350
Mixed malaria species infection, no. (%) 11 (2)
Gametocytaemia, no. (%) of patients 27 (4)
Gametocytaemia, geometric mean parasite/μL (95%CI) 255 (125 – 521
Haematocrit, % 35.6 (35.0 – 36
Glucose, mmol/L 6.1 (6.0 – 6.2)
Lactate, mmol/L 3.2 (3.1 – 3.3)
NOTE. Data are presented as mean values (95%CI), unless otherwise indicated. aDef
febrile illness with a positive malaria slide. *Only children aged ≥ 4 years were askedOutcome measures
Fever and parasite clearance times, post-treatment
haematocrit at all time points and gametocyte rates
were not significantly different between patients who
received thiamin and placebo (Table 3). Baseline (day 0)
and day 35 and 42 mean haematocrit improved signifi-
cantly after treatment for both groups (Paired t-test p <
0.001 for both groups, Table 3).
Of 50 (8%) patients (20 in thiamin and 30 in placebo
arms) with subsequent P. falciparum reappearance, PCR
genotyping indicated that 17/50 (34%) had recrudescent
infections [6/20 (30%) in thiamin and 11/30 (37%) in
placebo groups, (p = 0.64)]. One patient in placebo group
with P. falciparum reappearance had an indeterminateils for patients included in the study on thiamin
oups
Thiamin (n = 314) Placebo (n = 316)
155 (49) 162 (51)
9 (0.5 – 63) 8 (0.7 – 73)
204 (65) 210 (66)
.4) 28.7 (26.8 – 30.7) 27.5 (25.6 – 29.3)
124.4) 122.8 (119.5 – 126.0) 121.5 (118.5 – 124.8)
85 (27) 81 (26)
.5) 38.4 (38.3 – 38.5) 38.5 (38.3 – 38.6)
85 (27) 74 (23)
01.9) 100.7 (99.2 – 102.2) 100.9 (99.4 – 102.4)
.7) 68.9 (67.6 – 70.1) 68.8 (67.7 – 70.0)
.5) 96.0 (94.4 – 97.6) 96.7 (95.2 – 98.3)
.6) 27.8 (27.1 – 28.6) 28.4 (27.7 – 29.1)
15 (12 – 15) 15 (4 – 15)
18 (6) 16 (5)
13 (4) 16 (5)
5.3 (5.0 – 5.7) 5.1 (4.7 – 5.7)
4 (0 – 10) 4 (0 – 10)
85/313 (27) 78/315 (25)
63/313 (20) 80/314 (25)
1/313 (0.3%) 1/316 (0.3)
– 29,499) 27,775 (22,995 – 33,549) 23,750 (19,369 – 29,123)
5 (2) 6 (2)
14 (4) 13 (4)
) 198 (78 – 503) 334 (98 – 1,134)
.1) 35.6 (34.8 – 36.4) 35.5 (34.7 – 36.3)
6.2 (6.1 – 6.3) 6.0 (5.9 – 6.2)
3.1 (3.0 – 3.2) 3.3 (3.1 – 3.4)
ined as patient or patient’s guardian reporting that the patient had had a
about these symptoms.
Table 2 Admission symptoms and signs for patients included in the study on thiamin treatment and Plasmodium
falciparum malaria in Laos
Symptoms and signs All (N = 630) Treatment groups
Thiamin (n = 314) Placebo (n = 316) P-value
Headache* 403/439 (92) 203/218 (93) 200/221 (90.5) 0.32
Headache visual analogue 5 (0 – 10) 5 (5 – 10) 5 (0 – 10) 0.60
score: median (range)*
Chill 569/630 (90) 281/314 (89) 288/316 (91) 0.48
Myalgia* 246/438 (56) 127/218 (58) 119/220 (54) 0.38
Weakness 600/629 (95) 297/313 (95) 303/316 (96) 0.55
Dizziness* 324/438 (74) 162/218 (74) 162/220 (74) 0.87
Dizziness visual analogue 4 (0 – 10) 4 (0 – 10) 4 (0 – 10) 0.98
score: median (range)*
Vertigo* 124/438 (28) 62/218 (28) 62/220 (28) 0.95
Tinnitus* 93/438 (21) 54/218 (25) 39/220 (18) 0.07
Anorexia 567/630 (90) 284/314 (90) 283/316 (90) 0.71
Nausea* 295/440 (67) 146/219 (67) 149/221 (67) 0.87
Vomiting 343/630 (54) 171/314 (54) 172/316 (54) 0.99
Abdominal pain* 123/448 (27) 64/220 (29) 59/228 (26) 0.44
Diarrhoea 130/629 (21) 74/314 (24) 56/315 (18) 0.07
Insomnia* 372/630 (59) 185/314 (59) 187/316 (59) 0.98
Nightmare* 40/438 (9) 19/218 (9) 21/220 (10) 0.76
Palpitation* 186/439 (42) 95/219 (43) 91/220 (41) 0.67
Dyspnoea* 160/627 (25.5) 71/312 (23) 89/315 (28) 0.11
Cough 142/630 (22) 60/314 (19) 82/316 (26) 0.04
Sore throat* 55/447 (12) 24/222 (11) 31/225 (14) 0.34
Irritable 22/628 (3.5) 9/313 (3) 13/315 (4) 0.39
Rash 1/630 (0.2) 1/314 (0.3) 0 0.31
Urticaria 4/630 (0.6) 2/314 (0.6) 2/316 (0.6) 0.99
Itch 4/630 (0.6) 1/314 (0.3) 3/316 (1) 0.32
Chest abnormality** 2/630 (0.3) 0 2/316 (0.6) 0.16
Drowsiness 19/630 (3) 10/314 (3) 9/316 (3) 0.80
Seizure 21/630 (3) 12/314 (4) 9/316 (3) 0.49
Jaundice 1/630 (0.2) 1/314 (0.3) 0 0.31
NOTE. Data are shown as number (%) unless otherwise indicated, *Only children aged ≥ 4 years were asked about these symptoms, **Chest abnormality:
crepitation, rhonchi.
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http://www.malariajournal.com/content/13/1/275PCR result and, considering this patient as having a re-
crudescent infection, the overall 42-day cure rates per
protocol, excluding patients who were lost to follow
up, withdrew consent, had persistent vomiting, or re-
infection, were 97% (599/617) [98% (303/309) for thiamin
and 96% (296/308) for placebo groups, p = 0.16] [3].
Including the patients with repeated vomiting, those
lost to follow up or withdrew (censored at the time last
seen), the undetermined PCR result, and recrudescences
all as failures gave 42-day PCR uncorrected cure rates
(95%CI) by survival analysis (Kaplan-Meier) of 93.5%
(90.1 – 95.8%) for thiamin and 90.3% (86.5 – 93.1%) forplacebo groups. For the PCR adjusted survival analysis,
the cure rates (95%CI) were 98.0% (95.7 – 99.1%) and
96.1% (93.2 – 97.8%) for thiamin and placebo groups, re-
spectively [3].
By conventional ITT analysis, the overall 42-day cure
rates, adjusted for re-infection, were 97% (612/630) [98%
(308/314) for thiamin and 96% (304/316) for placebo
groups, p = 0.15]. Of 18 patients (6 in thiamin and 12 in
placebo groups) considered as having recrudescent in-
fection, 16 (6 in thiamin and 10 in placebo groups) had
parasite recurrence at or before day 28. The 28-day cure
rates by ITT analysis were 308/314 (98%) for thiamin
Table 3 Outcome measures for the treatment of patients included in the study on thiamin treatment and Plasmodium
falciparum malaria in Laos†
Variables Treatment groups
All (N = 630) Thiamin (n = 314) Placebo (n = 316)
P. falciparum recurrence, no. (%)a 50 (8) 20 (6) 30 (9)
42-day cure rate, no. (%) of patientsa 612/630 (97) 308/314 (98) 304/316 (96)
42-day cure rate per protocol, no. (%) of patientsΨ 599/617 (97) 303/309 (98) 296/308 (96)
Fever clearance time, mean hours (95%CI)a,b 26.5 (25.1 – 27.9) 26.6 (24.7 – 28.6) 26.4 (24.4 – 28.4)
Patients remained febrile at day 1, no. (%) 317 (50) 157 (50) 160 (51)
Patients remained febrile at day 2, no. (%) 86 (14) 44 (14) 42 (13)
Parasite clearance time, median days (range)a,c 1 (1–3) 1 (1–3) 1 (1–3)
Positive parasitaemia at day 1, no. (%) of patients 191/627 (30) 98/311 (31.5) 93/316 (29)
Positive parasitaemia at day 2, no. (%) of patients 1 0 1
Gametocytaemia detected at anytime, no. (%) of patients 31 (5) 15 (5) 16 (5)
Gametocytaemia after treatment, no. (%) of patients 4 (0.6) 1 (0.3) 3 (1)
Gametocyte clearance time, median days (range)d 7 (1 – 21) 7 (1–14) 7 (7 – 21)
Gametocyte cleared by day 7, no. (%)d 28 (90) 14 (93) 14 (87.5)
Median (range) gametocyte-person-weeksd 0.42 (0.14 – 1.0) 0.42 (0.14 – 1.0) 0.42 (0.14 – 0.42)
P. vivax appearance after treatment for P. falciparum, no. (%) of patients 21/630 (3) 8/314 (2.5) 13/316 (4)
Day 0 haematocrit, mean % (95%CI) 35.6 (35.0 – 36.1) 35.6 (34.8 – 36.4) 35.5 (34.7 – 36.3)
Day 1 haematocrit, mean % (95%CI) 32.0 (31.5 – 32.5) 32.1 (31.4 – 32.8) 31.9 (31.1 – 32.6)
Day 2 haematocrit, mean % (95%CI) 30.7 (30.2 – 31.2) 30.9 (30.2 – 31.6) 30.6 (29.9 – 31.3)
Day 3 haematocrit, mean % (95%CI) 30.7 (30.2 – 31.2) 30.9 (30.2 – 31.6) 30.6 (29.9 – 31.3)
Day 7 haematocrit, mean % (95%CI) 32.9 (32.5 – 33.3) 33.1 (32.5 – 33.7) 32.7 (32.1 – 33.3)
Day 14 haematocrit, mean % (95%CI) 34.0 (33.7 – 34.4) 34.1 (33.6 – 34.7) 33.9 (33.4 – 34.5)
Day 21 haematocrit, mean % (95%CI) 35.4 (35.0 – 35.0) 35.4 (34.9 – 35.9) 35.3 (34.8 – 35.8)
Day 28 haematocrit, mean % (95%CI) 35.9 (35.6 – 36.3) 36.0 (35.5 – 36.5) 35.8 (35.4 – 36.3)
Day 35 haematocrit, mean % (95%CI) 36.3 (36.0 – 36.7) 36.3 (35.8 – 36.8) 36.3 (35.8 – 36.8)
Day 42 haematocrit, mean % (95%CI) 37.5 (37.1 – 37.8) 37.5 (37.0 – 38.0) 37.5 (37.0 – 38.0)
NOTE. †No statistical difference was found between thiamin and placebo groups.
ΨThe patient with undetermined PCR result was classified as recrudescent infection.
aIntention-to-treat analysis.
bData were available from 295 and 306 patients in thiamin and placebo groups, respectively.
cData were available from 311 and 316 patients in thiamin and placebo groups, respectively.
dData were available from 15 and 16 patients in thiamin and placebo groups, respectively.
Figure 2 Basal erythrocyte transketolase activity in micromoles/
min/gHb, shown as median in histogram and range in error bar.
(*significant difference from D42).
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(range) interval to recrudescent falciparum infections
was 21 (14–42) days. By ITT and per protocol analyses,
the 42-day PCR uncorrected cure rates for thiamin and
placebo groups were 294/314 (94%) vs 286/316 (90.5%);
(p = 0.15), and 289/309 (94%) vs 278/308 (90%), (p =
0.14), respectively. There were 21 episodes of vivax mal-
aria during the follow-up period, of which 8 (38%) were
in the thiamin group and the median (range) interval to
P. vivax appearance was 30 (21–42) days [3].
Thiamin status before and after anti-malarial and thiamin/
placebo treatments
Figures 2, 3 and 4 show the thiamin status before (day 0)
and after (day 42) anti-malarial and thiamin/placebo
Figure 3 Activated erythrocyte transketolase activity in micromoles/
min/gHb, shown as median in histogram and range in error bar.
(*significant difference from D42).
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http://www.malariajournal.com/content/13/1/275treatments. The admission median (range) basal and
activated ETK values for all study patients were 0.46
(0.12 – 3.75) and 0.54 (0.14 – 4.19) micromoles/min/
gHb, respectively. These were not significantly differ-
ent between thiamin and placebo groups (p = 0.98 and
p = 0.78, respectively). Admission mean alpha values
were also similar between the two groups (Table 4).
The overall percentage of patients with thiamin defi-
ciency (defined as alpha ≥25%) on admission was 27%
and with severe thiamin deficiency (defined as alpha >
31%) 9%, with no significant differences between the
groups (p = 0.13 and p = 0.33, respectively). For the 21
infants recruited (age 6–12 months), the admission
median (range) basal and activated ETK were 0.52
(0.15-3.75) and 0.62 (0.21-4.19) micromoles/min/gHb,
respectively. The mean alpha and the frequency of
thiamin deficiency on admission were similar between
the infants and children aged 1–15 years (p > 0.05).
At day 42, the overall median (range) basal and acti-
vated ETK values were 0.70 (0.16–3.91) and 0.80 (0.19–
4.47) micromoles/min/gHb, respectively and these values
were significantly higher in the thiamin compared to the
placebo groups [0.78 (0.33–2.64) vs 0.64 (0.16–3.91), p <
0.001; and 0.87 (0.36–2.66) vs 0.74 (0.19–4.47), p < 0.001),Figure 4 Alpha shown as mean in histogram and 95%CI.
(*significant difference from D42).respectively]. The mean (95%CI) day 42 alpha values were
significantly lower in the thiamin [12 (11–13)%] compared
to the placebo [17 (16–17)%] groups (p < 0.001). The over-
all proportion of patients with thiamin deficiency at day
42 was 6% and with severe thiamin deficiency was 2% and
was significantly lower in the thiamin (2% overall and 1%
severe deficiency) compared to the placebo (11% overall
and 3% severe deficiency) groups (p < 0.001 and p = 0.05),
respectively.
Following anti-malarial and thiamin/placebo treatments,
there was a significant decrement in alpha. For 614 pa-
tients with paired admission and day 42 samples, the
overall mean (95%CI; range) percentage change in
alpha was −5.7 (−6.4 to −5.0; −53 to 20)% (paired t-test
p < 0.001); −7.8 (−8.9 to −6.8; −53 to 20)% in the thia-
min group and −3.6 (−4.6 to −2.7; −38 to 16)% in the
placebo group (paired t-test p < 0.001 for both). The
mean (95%CI) changes in basal and activated ETK (mi-
cromoles/min/gHb) values between the thiamin versus
placebo groups were [0.34 (0.32 – 0.37) vs 0.18 (0.16 –
0.20), p < 0.001] and [0.35 (0.32 – 0.37) vs 0.20 (0.18 –
0.22), p < 0.001], respectively.
Higher admission and day 42 basal and activated ETK
but lower admission and day 42 alpha values were ob-
served among children compared to adults (p < 0.001 for
all). The proportion of patients with thiamin deficiency
(alpha ≥ 25%) was also significantly higher in the adults
[89/216 (41%)] compared to children [80/414 (19%)] on
admission (p < 0001) and [24/209 (11%)] vs [14/405
(3%)] at day 42 (p < 0.001). The proportion of patients
with thiamin deficiency (alpha ≥ 25%) on admission and
at day 42 was significantly higher in males than in fe-
males [103/317 (32%) vs 66/313 (21%), p = 0.001] and
[27/308 (9%) vs 11/306 (4%), p = 0.008)], respectively.
Mean alpha values and the proportion of the patients
with thiamin deficiency on admission and at day 42 were
not statistically different between pregnant and non-
pregnant women (p > 0.05). The median (range) basal
and activated ETK on admission and at day 42 were sig-
nificantly higher in severe than in uncomplicated malaria
patients (p < 0.01). The proportion of patients with thiamin
deficiency on admission (alpha ≥ 25%) was significantly
lower in severe [3/34 (9%)] compared to uncomplicated
[166/596 (28%)] malaria (p = 0.01) but were similar for se-
vere [1/30 (3%)] and uncomplicated [37/584 (6%)] groups
at 42-day follow-up (p = 1.00).
Glucose and lactate before and after anti-malarial and
thiamin/placebo treatments
The mean (95%CI) whole blood glucose and lactate on
admission was similar between thiamin and placebo
groups (Table 1). Following anti-malarial and thiamin/
placebo treatments, the mean (95%CI) glucose and lac-
tate decreased in both thiamin and placebo groups. The
Table 4 Biochemical assays for thiamin status before and after anti-malarial treatment among patients included in the
study on thiamin treatment and Plasmodium falciparum malaria in Laos§
Variables Treatment groups
All (N = 630) Thiamin (n = 314) Placebo (n = 316) P-value
Basal erythrocyte transketolase activity, median (range)
micromoles/min/gHb on admission
0.46 (0.12 – 3.75) 0.46 (0.15 – 1.17) 0.45 (0.12 – 3.75) 0.98
Basal erythrocyte transketolase activity, median (range)
micromoles/min/gHb at day 42*
0.70 (0.16 – 3.91) 0.78 (0.33 – 2.64) 0.64 (0.16 – 3.91) <0.001
Activated erythrocyte transketolase activity, median (range)
micromoles/min/gHb on admission
0.54 (0.14 – 4.19) 0.55 (0.18 – 1.33) 0.54 (0.14 – 4.19) 0.78
Activated erythrocyte transketolase activity, median (range)
micromoles/min/gHb at day 42*
0.80 (0.19 – 4.47) 0.87 (0.36 – 2.66) 0.74 (0.19 – 4.47) <0.001
Alpha, mean (95%CI) on admission 20 (19 – 21) 20 (19 – 21) 20 (19 – 21) 0.54
Alpha, mean (95%CI) at day 42* 14 (13 – 15) 12 (11 – 13) 17 (16 – 17) <0.001
Alpha > 31% on admission, no (%) 55 (9) 24 (8) 31 (10) 0.33
Alpha > 31% at day 42*, no (%) 10 (2) 2 (1) 8 (3) 0.05
Alpha < 15% on admission, no (%) 185 (29) 87 (28) 98 (31) 0.36
Alpha < 15% at day 42*, no (%) 384 (63) 243 (79) 141 (46) <0.001
Alpha = 15 – 24% on admission, no (%) 248 (39) 139 (44) 109 (34) 0.012
Alpha = 15 – 24% at day 42*, no (%) 182 (30) 56 (18) 126 (41) <0.001
Alpha≥ 25% on admission, no (%) 169 (27) 76 (24) 93 (29) 0.13
Alpha≥ 25% at day 42*, no (%) 38 (6) 5 (2) 33 (11) <0.001
§Data were available from 307 and 307 patients in thiamin and placebo groups, respectively.
*All values were significantly different between admission and day 42 data (P < 0.001) except alpha values in placebo group (P = 0.09).
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(mmol/L) was significantly higher on admission than
that at day 42 [6.1 (6.0 – 6.2) and 3.2 (3.1 – 3.3) vs 5.2
(5.1 – 5.3) and 2.6 (2.5 – 2.7), p < 0.001 for both]. The
mean glucose at day 42 was not different between the
groups but the mean (95%CI) lactate (mmol/L) at day 42
was slightly lower in the thiamin [2.5 (2.4 – 2.6)] than in
the placebo [2.7 (2.6 – 2.8)] groups, (p = 0.048).
Among patients with severe malaria (n = 34), the mean
glucose and lactate also significantly decreased following
anti-malarial and thiamin/placebo treatments with the
mean (95%CI) difference between admission and day 42
of 1.2 (0.6 – 1.9) mmol/L for glucose and 2.4 (1.8 – 3.0)
mmol/L for lactate. The admission versus day 42 mean
(95%CI) glucose (mmol/L) and lactate (mmol/L) among
this group of patients was [6.3 (5.7 – 6.8) vs 5.0 (4.7 –
5.2); p < 0.001] and [5.4 (4.6 – 6.1) vs 2.7 (2.3 – 3.0); p <
0.001], respectively.
No consistent relationships were observed between
lactate and basal and activated ETK or alpha at admis-
sion and day 42.
Post-treatment possible adverse events
No patient had obvious symptoms or signs suggesting
thiamin deficiency on admission or during or after treat-
ment. Adverse event symptoms were recorded for only
those 461 (73%) patients aged >4 years old and able toanswer questions (Table 4). There were no deaths nor
serious adverse events reported, including organ failure,
during follow up. Except for diarrhoea, which was sig-
nificantly more common in the placebo (7%) compared
to thiamin (3%) groups (p = 0.04), adverse events did not
significantly differ between thiamin and placebo groups.
Except for the proportion of dizziness at day 1, which
was significantly higher in the placebo (33%) compared
to thiamin (25%) groups (p = 0.045), the proportions of
the patients with dizziness, nightmare and headache fol-
lowing treatment at day 0, 2, 3, 7, 14, 21, 28, 35 and 42
were similar between the groups (p > 0.05). The median
(range) dizziness and headache VAS scores after treat-
ment at all time points did not differ significantly be-
tween the two groups for all patients and for only adults
(p > 0.05; Table 5). The median (range) basal and acti-
vated ETK and the mean (95%CI) alpha on admission
and at day 42 were not significantly different between
patients with and without dizziness, headache or night-
mares (p > 0.05).
For both groups combined, the admission and day 42
median (range) basal and activated ETK were signifi-
cantly higher in patients without any subsequent adverse
events compared to those with at least one subsequent
adverse effect (p < 0.0001 for all). Admission mean (95%
CI) alpha was significantly lower in patients without
subsequent adverse events [18% (17-19%) than in the
Table 5 Possible adverse events (AE) found in patients included in the study on thiamin treatment and Plasmodium
falciparum malaria in Laos*
Variables Treatment groups
All (N = 630) Thiamin (n = 314) Placebo (n = 316) P-value
At least one adverse event 226/630 (36%) 101/314 (32%) 125/316 (40%) 0.053
Headache 33/438 (7.5%) 18/219 (8%) 15/219 (7%) 0.58
Insomnia 36/629 (6%) 15/313 (5%) 21/316 (7%) 0.32
Weakness 33/629 (5%) 15/313 (5%) 18/316 (6%) 0.61
Anorexia 35/629 (6%) 15/313 (5%) 20/316 (6%) 0.40
Diarrhoea 31/630 (5%) 10/314 (3%) 21/316 (7%) 0.04
Nightmare 17/439 (4%) 5/219 (2%) 12/220 (5%) 0.08
Abdominal pain 12/447 (3%) 6/221 (3%) 6/226 (3%) 0.97
Dizziness 12/438 (3%) 4/219 (2%) 8/219 (4%) 0.24
Vomiting 14/629 (2%) 4/313 (1%) 10/316 (3%) 0.10
Nausea 5/440 (1%) 2/221 (1%) 3/219 (1%) 0.65
Palpitation 5/439 (1%) 1/220 (0.5%) 4/219 (2%) 0.17
Itch 5/629 (1%) 2/313 (1%) 3/316 (1%) 0.66
Vertigo 1/438 (0.2%) 0 1/219 (0.5%) 0.32
Tinnitus 1/440 (0.2%) 0 1/220 (0.45%) 0.32
Rash 1/629 (0.2%) 1/313 (0.3%) 0 0.31
Urticaria 1/629 (0.2%) 0 1/316 (0.3%) 0.32
Irritability 0 0 0 -
Dyspnoea 1/629 (0.2%) 1/313 (0.3%) 0 0.31
Hearing loss 0 0 0 -
Paraesthesia 2/441 (0.5%) 1/221 (0.5%) 1/220 (0.5%) 0.99
*Symptoms are given for only those 461 patients aged > 4 years old and able to answer questions about these symptoms, except that parents/guardians were
asked about their charges insomnia, weakness, anorexia and itch.
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(p < 0.001). The corresponding values at day 42 were
13% (12-14%) for those without adverse events and
16% (15-17%) for those with at least one adverse event
(p < 0.001). The proportion of patients with thiamin
deficiency (alpha ≥ 25%) was significantly higher in those
with at least one adverse event compared to those
without adverse events [88/226 (39%) vs 81/404 (20%),
p < 0.001] on admission and [29/218 (13%) vs 9/396
(2%), p < 0.001] at day 42, respectively. The proportion
of the patients with at least one possible adverse event
and the frequency of various side effects among the
patients with severe malaria (n = 34) were not different
between the thiamin and placebo groups (p > 0.05).
Adverse events only in the first and last week were
similar between thiamin and placebo groups (p > 0.05
for all).
Discussion
A large randomized, double-blind, parallel group, placebo-
controlled trial to compare the incidence of adverse events
between malaria patients who were supplemented withand without thiamin in addition to standard ACT treat-
ment was conducted. No major differences were identified
between the two groups so the trial was discontinued, fol-
lowing the interim analyses of data from 630 recruited pa-
tients. The incidence of adverse effects, including
dizziness, headache and nightmare, and the proportion of
the patients with one or more subsequent adverse effects
was not statistically different between the thiamin and pla-
cebo groups, suggesting that oral thiamin supplementa-
tion does not reduce adverse effects during and after anti-
malarial treatment. In contrast with the post-hoc analysis
of data published by Mayxay et al. [6], admission and day
42 median basal and activated ETK and alpha were not
significantly associated with the occurrence of dizziness,
headache and nightmares. However, for all patients com-
bined, lower admission and day 42 median basal and acti-
vated ETK and higher alpha were significantly associated
with the occurrence of at least one adverse event, suggest-
ing that there be some minor relationship between thia-
min status and adverse events.
Limitations of the study include a delay of 7–17
months between sample collection and ETK assays, the
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mediate treatment of those with severe malaria and the
relative rarity of patients with severe malaria recruited to
the study.
In the study of Mayxay et al. [6], it was unclear
whether the improvement in thiamin status was a conse-
quence of recovery from malaria or thiamin supplemen-
tation (as all patients were supplemented with thiamin
1 mg/day) or both. In this trial, the frequency and sever-
ity of thiamin deficiency were significantly lower at 42-
day follow-up in both thiamin and placebo groups
compared with admission with acute malaria, but with a
significantly greater improvement in the thiamin treated
group, suggesting that thiamin status improvement was
a consequence of both recovery from malaria and sup-
plementation. Since increment of body temperature by
1°C increases basal metabolic rate by 10%, malaria fever
and increased metabolic rate augments the utilization of
thiamin and, therefore, may precipitate deficiency in
those with low dietary intakes [10]. Earlier research from
western Thailand, that adults with severe falciparum
malaria had higher alpha values than those with uncom-
plicated malaria, was not confirmed [5]. Indeed, in Laos
it was found that the proportion of patients with raised
alpha was significantly lower in patients with severe than
those with uncomplicated malaria. Although the propor-
tion of patients with severe malaria was lower in Laos,
the authors were unable to explain this difference. In
the current report, 27% of patients presenting with
malaria had biochemical thiamin deficiency and 9%
had severe deficiency on admission – similar to that
reported in Mayxay et al. [6] at 30% and 12%, respect-
ively, conducted at Phalanxay Clinic in the same prov-
ince. In Vientiane, clinically unapparent thiamin deficiency
among infants is also common: ~13% of sick infants
but without clinical evidence of beriberi admitted to
hospital had biochemical thiamin deficiency [7]. Se-
vere biochemical thiamin deficiency in Lao infants
with malaria could be expected, but malaria is rela-
tively rare in Lao infants – in 2010 of 1,097 patients
with malaria diagnosed in the three southern provinces
of Laos, 21 (~2%) were infants (Mayxay M, personal
communication).
Lao adults have multiple risk factors for thiamin de-
ficiency including hard physical labour of rice farm-
ing, alcohol intake, consumption of polished rice and
thiaminase-containing food, such as “paa dek” (fer-
mented fish paste), and thiamin antagonists such as
betel nut. The significantly higher prevalence of bio-
chemical thiamin deficiency on admission and at 42-day
follow-up among adults (≥15 years) compared to children
aged <15 years old suggests that hard physical labour of
the rural rice-farming adults may play an important role
in biochemical thiamin deficiency [10].Conclusion
Thiamin supplementation did not reduce the frequency
of adverse events after anti-malarial therapy among pa-
tients with falciparum malaria in southern Laos. Thiamin
supplementation could help to reduce biochemical
thiamin deficiency among malaria patients following
anti-malarial drug treatment, but this did not have a
measurable clinical or parasitological impact.
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